

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: STEWARD, et al.	)	Examiner:
	)	
Serial Number: Pending	)	Art Unit:
	)	
Filed: Herewith	)	
	)	
For: MODIFIED CLOSTRIDIAL	)	
NEUROTOXINS WITH	)	
<u>BIOLOGICAL PERSISTENCE</u>	)	Irvine, California

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:


Applicant provides with regard to the patent application entitled MODIFIED CLOSTRIDIAL NEUROTOXINS WITH BIOLOGICAL PERSISTENCE, filed herewith one copy of a documents of which <sup>they are</sup> ~~he is~~ aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the 6 documents submitted is set forth on the attached 1 page Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: October 31, 2001

  
Stephen Donovan  
Registration Number 33,433

Please direct all inquiries and correspondence to:

Stephen Donovan  
Allergan, Inc.  
Tower Two, Seventh Floor  
2525 Dupont Drive  
Irvine, California 92623-9534

**CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10**

I hereby certify that this Supplementary Information Disclosure Statement and the documents referred to as enclosed herein are being deposited with the United States Postal Service on this date October 31, 2001 in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EL385559034US addressed to Assistant Commissioner for Patents, Washington, D.C. 20231

Susan Bartholomew  
Name of person mailing paper

  
Signature of person mailing paper

Date: October 31, 2001

**SUPPLEMENTAL  
LIST OF ART CITED BY APPLICANT**

ATTY. DOCKET: 17376 (AP)	SERIAL NO.: PENDING
APPLICANT: STEWARD, et al.	TITLE: MODIFIED CLOSTRIDIAL NEUROTOXINS WITH BIOLOGICAL PERSISTENCE
FILING DATE: HEREWITH	GROUP:

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	6,113,915	9/5/00	AOKI, et al.	514		
	AB						
	AC						
	AD						
	AE						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)

**OTHER ART**

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Li Li and Bal Ram Singh, <i>Isolation of Synaptotagmin as a Receptor for Types A and E Botulinum Neurotoxin and Analysis of their Comparative Binding Using a new Microtiter Plate Assay</i> , Journal of Natural Toxins, Vol. 7, No. 3, 1998, Pgs. 215-226
	CB	E. Erdal, et al., <i>Processing of Tetanus and Botulinum A Neurotoxins in Isolated Chromaffin Cells</i> , Naunyn-Schmiedeberg's Arch Pharmacol (1995) 351:67-78
	CC	D. A. Raciborska and M. Charlton, <i>Retention of cleaved synaptosome-associated protein of 25 kDa (SNAP-25) in neuromuscular junctions: a new hypothesis to explain persistence of botulinum A poisoning</i> , Can. J. Physiol. Pharmacol. 77: 679-688 (1999)
	CD	A. Varshavsky, <i>The N-end rule: Functions, mysteries, uses</i> , Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 12142-12149, October 1996 Biochemistry.
	CE	J.E. Keller, et al., <i>Persistence of botulinum neurotoxin action in cultured spinal cord cells</i> <sup>1,2</sup> , FEBS 22397 FEBS Letters 456, (1999) 137-142

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.